Reevaluating the Role of High-Density Lipoprotein Cholesterol: New Perspectives on Cardiovascular Disease and Alzheimer Disease
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Reevaluating the Role of High-Density Lipoprotein Cholesterol : New Perspectives on Cardiovascular Disease and Alzheimer Disease. / Kjeldsen, Emilie Westerlin; Luo, Jiao; Nordestgaard, Liv Tybjærg; Sandau, Nicolai; Frikke-Schmidt, Ruth.
In: Clinical Chemistry, Vol. 69, No. 12, 2023, p. 1329-1332.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Reevaluating the Role of High-Density Lipoprotein Cholesterol
T2 - New Perspectives on Cardiovascular Disease and Alzheimer Disease
AU - Kjeldsen, Emilie Westerlin
AU - Luo, Jiao
AU - Nordestgaard, Liv Tybjærg
AU - Sandau, Nicolai
AU - Frikke-Schmidt, Ruth
PY - 2023
Y1 - 2023
N2 - High-density lipoprotein (HDL) cholesterol has for decades been considered as the “good cholesterol” due to its inverse association with cardiovascular disease (CVD) risk in observational studies. However, human genetic studies have failed to establish a direct causal association between low HDL cholesterol concentrations and CVD. Moreover, the development of HDL cholesterol-increasing drugs has been pursued, yet their efficacy in reducing cardiovascular risk has been limited. Interestingly, recent studies now uncover unexpected relationships between high HDL cholesterol concentrations and several diseases. These studies, including 2 significant recent investigations, observe associations between high HDL cholesterol concentrations, all-cause mortality, cardiovascular mortality, and Alzheimer disease (1, 2). This perspective aims to summarize and discuss these emerging findings and their potential implications for our understanding of HDL cholesterol and for its use in clinical practice, focusing on the complex interplay between HDL cholesterol, disease risk, and underlying mechanisms.
AB - High-density lipoprotein (HDL) cholesterol has for decades been considered as the “good cholesterol” due to its inverse association with cardiovascular disease (CVD) risk in observational studies. However, human genetic studies have failed to establish a direct causal association between low HDL cholesterol concentrations and CVD. Moreover, the development of HDL cholesterol-increasing drugs has been pursued, yet their efficacy in reducing cardiovascular risk has been limited. Interestingly, recent studies now uncover unexpected relationships between high HDL cholesterol concentrations and several diseases. These studies, including 2 significant recent investigations, observe associations between high HDL cholesterol concentrations, all-cause mortality, cardiovascular mortality, and Alzheimer disease (1, 2). This perspective aims to summarize and discuss these emerging findings and their potential implications for our understanding of HDL cholesterol and for its use in clinical practice, focusing on the complex interplay between HDL cholesterol, disease risk, and underlying mechanisms.
U2 - 10.1093/clinchem/hvad126
DO - 10.1093/clinchem/hvad126
M3 - Journal article
C2 - 37700571
AN - SCOPUS:85178649748
VL - 69
SP - 1329
EP - 1332
JO - Clinical Chemistry
JF - Clinical Chemistry
SN - 0009-9147
IS - 12
ER -
ID: 377949425